Plasma and Urinary Biomarkers of Kidney Injury in Daratumumab-Treated Multiple Myeloma Patients

Study start date: September 1, 2024

Inclusion Criteria: * Patients must be ≥ 18 years of age * Patients can be on a clinical trial * Patients must have had a confirmed new diagnosis of MM following revised IMWG criteria 1. New diagnosis of systemic multiple myeloma defined as no documented history of prior multiple myeloma. 2. Further, no prior systemic treatment with anti-myeloma agent is permitted with the exception of corticosteroids for no more than 4 weeks. 3. Prior history of receiving radiation therapy for the treatment of plasmacytoma or lytic lesions, is permitted on the study. * Patients receiving SC daratumumab * Patients must be able to sign the informed consent * Patients must be at risk for AKI and meet at least two of the three following criteria: age ≥65; baseline eGFR \<60; or use of NSAIDs (not including aspirin), bisphosphonates, intravenous contrast, diuretics, or RAS inhibitors in the 14 days preceding treatment initiation Exclusion Criteria: * End stage renal disease (e.g, on long-term dialysis or with a kidney transplant and on long-term dialysis) at the time of starting daratumumab * Acute kidney injury defined as a ≥1.5-fold rise in baseline SCr, where baseline SCr is the lowest SCr in the 365 days preceding receipt of daratumumab, or with AKI on RRT * Previous exposure to daratumumab or other anti-CD38 therapy * Patients receiving intravenous daratumumab * Exposure to concomitant chemotherapy which could be perceived as nephrotoxic within 30 days of receipt of daratumumab (e.g., cisplatin, mTOR inhibitors) * Moribund patients (e.g., those expected to die in the next 30 days from the time of screening)